MedinCell (MEDCL) Panoramica del titolo
MedinCell S.A., azienda farmaceutica, sviluppa in Francia prodotti iniettabili a lunga durata d'azione in diverse aree terapeutiche. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 6/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 1/6 |
| Dividendi | 0/6 |
MEDCL Community Fair Values
Create NarrativeSee what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di MedinCell S.A.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | €26.68 |
| Massimo di 52 settimane | €39.68 |
| Minimo di 52 settimane | €15.00 |
| Beta | 1 |
| Variazione di 1 mese | 15.20% |
| Variazione a 3 mesi | 6.98% |
| Variazione di 1 anno | 58.15% |
| Variazione a 3 anni | 298.80% |
| Variazione a 5 anni | 147.04% |
| Variazione dall'IPO | 262.99% |
Notizie e aggiornamenti recenti
Aggiornamento della narrazione • Apr 27
MEDCL: Long-Acting Schizophrenia Injection Progress Will Drive Future Upside
The analyst price target for MedinCell has increased slightly from €33.85 to €34.28 as analysts adjust their assumptions for revenue growth, profit margins and future P/E expectations. What's in the News MedinCell and Teva Pharmaceuticals reported that the U.S. FDA accepted the New Drug Application for TEV-'749, an investigational once monthly olanzapine extended release injectable suspension for adults with schizophrenia, using MedinCell's SteadyTeq copolymer technology (Key Developments).Aggiornamento della narrazione • Apr 10
MEDCL: Schizophrenia Injection And 2026 Sales Outlook Will Drive Upside
Narrative Update on MedinCell The analyst price target for MedinCell remains steady at €33.85, as analysts keep their fair value view, discount rate, revenue growth outlook and profit margin assumptions essentially unchanged. What's in the News MedinCell completed a follow on equity offering of 2,370,000 ordinary shares, raising €48.2295 million at a price of €20.35 per share, via a subsequent direct listing (Key Developments).Aggiornamento della narrazione • Mar 27
MEDCL: 2026 Revenue Ramp And Schizophrenia Launch Will Drive Upside
Analysts now set their price target for MedinCell at €33.85, slightly below the prior €34.23. This reflects updated assumptions on long term profit margins and a higher future P/E multiple in their models.Aggiornamento della narrazione • Mar 11
MEDCL: 2026 Sales Outlook And New Schizophrenia Therapy Will Drive Upside
Analysts have trimmed their price target on MedinCell by about €1.04 to reflect an updated fair value of €34.23, as they factor in revised assumptions around revenue growth, profit margins and future P/E expectations. What's in the News MedinCell completed a follow on equity offering of ordinary shares, raising about €48.23 million by issuing 2,370,000 shares at €20.35 per share, via a subsequent direct listing (Key Developments).Recent updates
Aggiornamento della narrazione • Apr 27
MEDCL: Long-Acting Schizophrenia Injection Progress Will Drive Future Upside
The analyst price target for MedinCell has increased slightly from €33.85 to €34.28 as analysts adjust their assumptions for revenue growth, profit margins and future P/E expectations. What's in the News MedinCell and Teva Pharmaceuticals reported that the U.S. FDA accepted the New Drug Application for TEV-'749, an investigational once monthly olanzapine extended release injectable suspension for adults with schizophrenia, using MedinCell's SteadyTeq copolymer technology (Key Developments).Aggiornamento della narrazione • Apr 10
MEDCL: Schizophrenia Injection And 2026 Sales Outlook Will Drive Upside
Narrative Update on MedinCell The analyst price target for MedinCell remains steady at €33.85, as analysts keep their fair value view, discount rate, revenue growth outlook and profit margin assumptions essentially unchanged. What's in the News MedinCell completed a follow on equity offering of 2,370,000 ordinary shares, raising €48.2295 million at a price of €20.35 per share, via a subsequent direct listing (Key Developments).Aggiornamento della narrazione • Mar 27
MEDCL: 2026 Revenue Ramp And Schizophrenia Launch Will Drive Upside
Analysts now set their price target for MedinCell at €33.85, slightly below the prior €34.23. This reflects updated assumptions on long term profit margins and a higher future P/E multiple in their models.Aggiornamento della narrazione • Mar 11
MEDCL: 2026 Sales Outlook And New Schizophrenia Therapy Will Drive Upside
Analysts have trimmed their price target on MedinCell by about €1.04 to reflect an updated fair value of €34.23, as they factor in revised assumptions around revenue growth, profit margins and future P/E expectations. What's in the News MedinCell completed a follow on equity offering of ordinary shares, raising about €48.23 million by issuing 2,370,000 shares at €20.35 per share, via a subsequent direct listing (Key Developments).Aggiornamento della narrazione • Feb 25
MEDCL: 2026 Revenue Outlook And New Schizophrenia Drug Will Support Upside
Analysts have kept their price target for MedinCell steady at €35.26, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin and future P/E in their latest update. What's in the News Teva Pharmaceuticals and MedinCell announced that the U.S. FDA has accepted the New Drug Application for TEV-'749, an olanzapine extended-release injectable suspension for adult schizophrenia treatment, using MedinCell’s SteadyTeq copolymer technology for controlled sustained drug release (Key Developments).Aggiornamento della narrazione • Feb 09
MEDCL: 2026 Revenue Guidance Will Support Upside As Profitability Outlook Strengthens
Analysts have trimmed their price target on MedinCell to about €35.26 from roughly €36.16, citing slightly higher discount rate assumptions, modestly softer revenue growth expectations of around 61.5% and a lower projected profit margin of about 70.3%, partly offset by a higher assumed future P/E multiple near 14.5x. What's in the News MedinCell issued revenue guidance for 2026, with expected net sales in a range of $250 million to $280 million.Aggiornamento della narrazione • Jan 25
MEDCL: Index Inclusion Will Support Upside As Profitability Outlook Strengthens
Analysts have raised their price target on MedinCell to €36.16 from €35.10, citing updated assumptions that incorporate a higher projected profit margin along with a lower future P/E multiple in their models. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, which covers liquid small-cap companies across 23 developed markets, increasing its visibility to global equity investors who track MSCI benchmarks (Key Developments).Aggiornamento della narrazione • Jan 11
MEDCL: Index Inclusion Will Support Future Upside Potential
Analysts have raised their price target on MedinCell to €35.10. The latest update reflects adjusted expectations around revenue growth, profit margins and future P/E assumptions.Aggiornamento della narrazione • Dec 19
MEDCL: Index Inclusion And New FDA Label Will Drive Upside Potential
Analysts have marginally raised their price target on MedinCell from €34.39 to €35.10, citing slightly stronger long term revenue growth expectations that more than offset a modestly lower projected profit margin and a reduced future P E multiple. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, increasing its visibility among global institutional and index-tracking investors from 24 November 2025 (company announcement).Aggiornamento della narrazione • Dec 05
MEDCL: Future Index Inclusion Will Drive Visibility And Earnings Upside Potential
Analysts have modestly reduced their price target for MedinCell by approximately $0.49 per share, reflecting tempered expectations for revenue growth, partially offset by improved projected profit margins and slightly lower future valuation multiples. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, boosting its visibility among global institutional investors and index-tracking funds, effective at the opening of trading on 24 November 2025 (Client Announcement) The FDA has approved UZEDY, a once monthly, subcutaneous long acting risperidone injection using MedinCell’s SteadyTeq technology, for maintenance treatment of bipolar I disorder in adults, expanding its label beyond schizophrenia (Product Related Announcement) MedinCell plans to submit a New Drug Application in the US for Olanzapine LAI, a once monthly long acting injection for schizophrenia using its co polymer technology licensed to Teva, in the fourth quarter of 2025, following positive Phase 3 safety data (Product Related Announcement) UZEDY has received regulatory approval in South Korea and is showing strong commercial traction, with 2024 net sales of 117 million dollars and 95 million dollars already in the first half of 2025.Articolo di analisi • Dec 01
MedinCell S.A.'s (EPA:MEDCL) 27% Cheaper Price Remains In Tune With Revenues
MedinCell S.A. ( EPA:MEDCL ) shares have retraced a considerable 27% in the last month, reversing a fair amount of...Aggiornamento della narrazione • Nov 21
MEDCL: Index Inclusion Will Drive Increased Visibility And Market Confidence
Analysts have slightly reduced their fair value price target for MedinCell from $35.16 to $34.87, reflecting tempered expectations around revenue growth and profit margins. What's in the News MedinCell has been selected for inclusion in the MSCI World Small Cap Index, which may enhance visibility among institutional investors and index-tracking funds.Aggiornamento della narrazione • Nov 06
MEDCL: Profit Margins Are Expected To Improve Significantly With Recent FDA Approval
Analysts have raised their price target for MedinCell from $31.16 to $35.16. This change reflects increased confidence in the company’s future profitability and outlook, even though there is a slightly higher discount rate and moderated revenue growth projections.Aggiornamento della narrazione • Oct 23
Analysts Lift MedinCell Price Target on Strong Revenue Outlook and Positive Regulatory Developments
Analysts have raised their price target for MedinCell from €26.90 to €31.16, citing improved revenue growth projections and favorable updates to future earnings expectations as key drivers for this upward revision. What's in the News FDA approves UZEDY, a once-monthly, long-acting risperidone injection, as monotherapy or adjunctive therapy for maintenance treatment of bipolar I disorder in adults.Aggiornamento della narrazione • Oct 09
Global Expansion And Extended Patents Will Unlock Future Opportunities
Analysts have raised their price target for MedinCell from $24.47 to $26.90, citing stronger fair value projections and underlying optimism in the company’s financial outlook. What's in the News MedinCell plans to submit a New Drug Application (NDA) for Olanzapine LAI, a once-monthly long-acting treatment for schizophrenia, in the US during the fourth quarter of 2025 (Key Developments).Aggiornamento della narrazione • Sep 25
Global Expansion And Extended Patents Will Unlock Future Opportunities
The upward revision in MedinCell's price target reflects a significant increase in consensus revenue growth forecasts coupled with a notable decline in the future P/E ratio, resulting in a new fair value estimate of €24.47. What's in the News UZEDY, a long-acting injectable risperidone for schizophrenia, received regulatory approval in South Korea and will be distributed by Teva Handok.Articolo di analisi • Sep 25
Why Investors Shouldn't Be Surprised By MedinCell S.A.'s (EPA:MEDCL) 30% Share Price Surge
The MedinCell S.A. ( EPA:MEDCL ) share price has done very well over the last month, posting an excellent gain of 30...Nuova narrazione • Sep 05
Global Expansion And Extended Patents Will Unlock Future Opportunities
Key Takeaways Expansion of UZEDY and BEPO®-based programs, along with strong partnerships, underpin growth and reduce reliance on a single product. Extended patent protection and real-world value evidence support sustained pricing power and margin strength amid growing demand globally.Articolo di analisi • Jun 19
News Flash: Analysts Just Made A Substantial Upgrade To Their MedinCell S.A. (EPA:MEDCL) Forecasts
MedinCell S.A. ( EPA:MEDCL ) shareholders will have a reason to smile today, with the analysts making substantial...Articolo di analisi • Dec 25
Industry Analysts Just Made An Incredible Upgrade To Their MedinCell S.A. (EPA:MEDCL) Revenue Forecasts
MedinCell S.A. ( EPA:MEDCL ) shareholders will have a reason to smile today, with the analysts making substantial...Articolo di analisi • Jul 05
MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be
The latest analyst coverage could presage a bad day for MedinCell S.A. ( EPA:MEDCL ), with the analysts making...Articolo di analisi • Apr 26
Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%
Despite an already strong run, MedinCell S.A. ( EPA:MEDCL ) shares have been powering on, with a gain of 30% in the...Articolo di analisi • Jan 09
Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher
The MedinCell S.A. ( EPA:MEDCL ) share price has done very well over the last month, posting an excellent gain of 26...Articolo di analisi • Mar 02
The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On
MedinCell S.A. ( EPA:MEDCL ) shareholders might be concerned after seeing the share price drop 17% in the last month...Articolo di analisi • Jan 08
Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?
Every investor in MedinCell S.A. ( EPA:MEDCL ) should be aware of the most powerful shareholder groups. Large companies...Rendimenti per gli azionisti
| MEDCL | FR Pharmaceuticals | FR Mercato | |
|---|---|---|---|
| 7D | 2.5% | 1.6% | 2.1% |
| 1Y | 58.2% | -11.8% | 0.8% |
Ritorno vs Industria: MEDCL ha superato il French Pharmaceuticals che ha restituito -11.8 % nell'ultimo anno.
Rendimento vs Mercato: MEDCL ha superato il mercato French che ha restituito 0.8 % nell'ultimo anno.
Volatilità dei prezzi
| MEDCL volatility | |
|---|---|
| MEDCL Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in FR Market | 10.8% |
| 10% least volatile stocks in FR Market | 2.9% |
Prezzo delle azioni stabile: MEDCL non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato French.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di MEDCL è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2003 | 145 | Christophe Douat | www.medincell.com |
MedinCell S.A., azienda farmaceutica, sviluppa farmaci iniettabili a lunga durata d'azione in varie aree terapeutiche in Francia. Sviluppa soluzioni basate su BEPO, una tecnologia iniettabile a lunga durata d'azione, e offre UZEDY (mdc-IRM) per il trattamento della schizofrenia negli adulti. I prodotti dell'azienda in fase di sviluppo includono mdc-CWM, una formulazione a rilascio prolungato di celecoxib in fase III di sperimentazione per il trattamento della riduzione del dolore e dell'infiammazione postoperatoria, e mdc-TJK, un'iniezione sottocutanea in fase III di sperimentazione clinica per il trattamento della schizofrenia.
MedinCell S.A. Riepilogo dei fondamenti
| MEDCL statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | €957.92m |
| Utili (TTM) | -€19.95m |
| Ricavi(TTM) | €32.44m |
29.5x
Rapporto P/S-48.0x
Rapporto P/EMEDCL è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| MEDCL Conto economico (TTM) | |
|---|---|
| Ricavi | €32.44m |
| Costo del fatturato | €0 |
| Profitto lordo | €32.44m |
| Altre spese | €52.39m |
| Utili | -€19.95m |
Ultimi utili riportati
Sep 30, 2025
Prossima data di guadagno
Jun 16, 2026
| Utile per azione (EPS) | -0.56 |
| Margine lordo | 100.00% |
| Margine di profitto netto | -61.49% |
| Rapporto debito/patrimonio netto | -232.2% |
Come si è comportato MEDCL nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/26 21:34 |
| Prezzo dell'azione a fine giornata | 2026/05/26 00:00 |
| Utili | 2025/09/30 |
| Utili annuali | 2025/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
MedinCell S.A. è coperta da 13 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Seynnaeve | Degroof Petercam |
| Michael DiFiore | Evercore ISI |
| Raghuram Selvaraju | H.C. Wainwright & Co. |